Webcast—Individualized Management of Castration-Resistant Prostate Cancer: Navigating a Long and Winding Road
This CME-certified Webcast contains video and downloadable slides from the symposium Individualized Management of Castration-Resistant Prostate Cancer: Navigating a Long and Winding Road, a prIME Oncology educational activity that was held on Saturday, May 30, 2015 in Chicago, Illinois.
Daniel P. Petrylak, MDYale Cancer Center
New Haven, Connecticut, United States
Karim Fizazi, MD, PhDGustave Roussy
Neal Shore, MD, FACSCarolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina
This symposium is designed to meet the educational needs of medical oncologists, surgical and radiation oncologists, urologists, and other healthcare professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC).
After successful completion of this educational activity, participants should be able to:
- Employ best practices for patient selection, sequencing, and combining systemic treatment approaches in CRPC
- Evaluate emerging endocrine therapies, including novel androgen receptor-targeted therapies, for the management of CRPC
- Describe the mechanism of action and therapeutic activity of bone-targeted treatments in prostate cancer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME and Disclosure Information
This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals.
July 5, 2015
July 5, 2016